-
The Impact of Venous Thromboembolism on Upper Tract Urothelial Carcinomas Undergoing Open or Minimally Invasive Radical Nephroureterectomy in the USA: Perioperative Outcomes and Health Care Costs from Insurance Claims Data Eur. Urol. Focus (IF 5.4) Pub Date : 2024-03-02 Anas S. Tresh, Francesco Del Giudice, Shufeng Li, Satvir Basran, Federico Belladelli, Ettore De Berardinis, Vincenzo Asero, Matteo Ferro, Sabin Tataru, Gian Maria Busetto, Ugo Falagario, Riccardo Autorino, Felice Crocetto, Biagio Barone, Benjamin Pradere, Marco Moschini, Andrea Mari, Wojciech Krajewski, Łukasz Nowak, Bartosz Małkiewicz, Tomasz Szydełko, Simone Crivellaro, Abhay Rane, Benjamin Challacombe
Patients with preoperative venous thromboembolism (VTE) undergoing radical nephroureterectomy (RNU) have increased morbidity, postprocedure VTE, hospital length of stay, rehospitalizations, and hospital costs. The presented findings may contribute to the counseling process for patients with upper tract urothelial carcinoma and preoperative VTE by providing enhanced insights into the risks associated
-
Opportunistic Prostate Cancer Screening with Biparametric Magnetic Resonance Imaging (VISIONING) Eur. Urol. Focus (IF 5.4) Pub Date : 2024-02-23 Christian Wetterauer, Marc Matthias, Heike Pueschel, Alexander Deckart, Lukas Bubendorf, Ashkan Mortezavi, Emilio Arbelaez, David Jean Winkel, Tobias Heye, Daniel T. Boll, Elmar Merkle, Stefanie Hayoz, Helge H. Seifert, Cyrill A. Rentsch
Biparametric magnetic resonance imaging of the prostate is a promising and highly sensitive tool for prostate cancer screening and improves the detection of International Society of Urological Pathology ≥2 cancer by >60% as compared with the current screening tools of prostate-specific antigen and digital rectal examination.
-
A Double-blind, Randomised Four-way Crossover Study to Compare the Effects of Fesoterodine 4 and 8 mg Once Daily and Qxybutynin 5 mg Twice Daily After Steady-state Dosing Versus Placebo on Cognitive Function in Overactive Bladder–wet Patients over the Age of 75 Years with Mild Cognitive Impairment Eur. Urol. Focus (IF 5.4) Pub Date : 2024-02-23 Saima Rajabali, Prosper Asaana, Sahar Nazari, Adrian Wagg
Short-term fesoterodine, 4 and 8 mg daily, was not associated with any meaningful effect on the cognitive function of older adults with mild cognitive impairment (≥75 yr of age) and overactive bladder using a battery of cognitive tests.
-
Urologists and Sustainability: The First Survey from the French Sustainability Working Group Eur. Urol. Focus (IF 5.4) Pub Date : 2024-02-22 Michael Baboudjian, Alexandre de La Taille, Eric Lechevallier, Benjamin Pradere, Richard Mallet
-
Introducing WASHOUT: A Large-scale Observational Study of Inpatient Haematuria Eur. Urol. Focus (IF 5.4) Pub Date : 2024-02-22 Kevin G. Byrnes, Nikita R. Bhatt, Simona Ippoliti, Raghav Varma, Aqua Asif, Nikki Kerdegari, Alex Ng, Bing Chow, Quentin Mak, Arjun Nathan, Kevin Gallagher, Sinan Khadhouri, Veeru Kasivisvinathan
-
Risks of Dementia After Treatment with an Anticholinergic, Beta-3 Agonist, or Combination of Both for an Overactive Bladder: A Korean National Cohort Study Eur. Urol. Focus (IF 5.4) Pub Date : 2024-02-21 Jee Soo Park, Soo Beom Choi, Won Sik Jang, Jongchan Kim, Won Sik Ham
-
Pragmatic Approaches to Scalable Prehabilitation Eur. Urol. Focus (IF 5.4) Pub Date : 2024-02-16 Jessica Engle
-
Prehabilitation: A multidimensional adjunct to comprehensive personalized oncologic care. But, can we make it pragmatic? Eur. Urol. Focus (IF 5.4) Pub Date : 2024-02-15 Sarah P. Psutka
-
Personalized Reconstruction with Three-dimensional Printed Urological Tissue Constructs Eur. Urol. Focus (IF 5.4) Pub Date : 2024-02-06 Sang Jin Lee
Three-dimensional bioprinting technology presents innovative possibilities for patient-specific urological reconstructive surgery. However, successful implementation requires advances in imaging techniques, biomaterials, cell manipulation, and printing technologies. More importantly, collaboration between engineers and clinicians is imperative for realization of these advances.
-
Population Estimates of Ovarian Cancer Risk in a Cohort of Patients with Bladder Cancer Eur. Urol. Focus (IF 5.4) Pub Date : 2024-02-06 Laura Bukavina, Laura Davis, Emma Helstrom, Diana Magee, Lee Ponsky, Robert Uzzo, Adam Calaway, Philip Abbosh, Alexander Kutikov
We evaluated susceptibility to ovarian cancer (OC) in females with bladder cancer (BC) and germline variants linked to OC. Vulnerability to OC was observed for BC patients with these germline variants; however, the diagnosis of OC preceded the diagnosis of BC by 11–15 yr.
-
Let’s Be Practical: Home-based Moderate-intensity Exercise Interventions Are Needed Eur. Urol. Focus (IF 5.4) Pub Date : 2024-02-05 Sara Parke, Shreyas Joshi
Abstract not available
-
Use of Temporally Validated Machine Learning Models To Predict Outcomes of Percutaneous Nephrolithotomy Using Data from the British Association of Urological Surgeons Percutaneous Nephrolithotomy Audit Eur. Urol. Focus (IF 5.4) Pub Date : 2024-02-02 Robert M. Geraghty, Anshul Thakur, Sarah Howles, William Finch, Sarah Fowler, Alistair Rogers, Seshadri Sriprasad, Daron Smith, Andrew Dickinson, Zara Gall, Bhaskar K. Somani
We have developed a machine learning–based decision aid to provide patient-specific predictions for counselling patients and perioperative planning before percutaneous nephrolithotomy. The application is available online at .
-
Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202 Eur. Urol. Focus (IF 5.4) Pub Date : 2024-02-02 Kimberley S. Mak, Molly Scannell Bryan, James J. Dignam, William U. Shipley, Yue Lin, Christopher A. Peters, Elizabeth M. Gore, Seth A. Rosenthal, Kenneth L. Zeitzer, David P. D'Souza, Eric M. Horwitz, Thomas M. Pisansky, Jordan M. Maier, Susan M. Chafe, Tyler P. Robin, Mack Roach, Phuoc T. Tran, Luis Souhami, Jeff M. Michalski, Alan C. Hartford, Felix Y. Feng, Howard M. Sandler, Jason A. Efstathiou
With 19.6 yr of follow-up, RTOG 9202 revealed that 28 mo of androgen deprivation therapy (ADT) did not increase cardiovascular mortality versus 4 mo of ADT. For men with baseline cardiovascular disease, longer-term ADT may be associated with increased myocardial infarction mortality.
-
Re: Cathrine Alvær Vinje, Maria Nyre Vigmostad, Svein R. Kjosavik, Henrik Grönberg, Bjørnar Gilje, Svein Skeie. Prostate Biopsies Can Be Omitted in Most Patients with a Positive Stockholm3 Test and Negative Prostate Magnetic Resonance Imaging. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.08.009 Eur. Urol. Focus (IF 5.4) Pub Date : 2024-01-29 Wujianhong Liu, Yanyan He, Bin Yang
Abstract not available
-
Impact of Prostate Size on the Functional and Oncological Outcomes of Robot-assisted Radical Prostatectomy Eur. Urol. Focus (IF 5.4) Pub Date : 2024-01-29 Abdel Rahman Jaber, Marcio Covas Moschovas, Shady Saikali, Ahmed Gamal, Roshane Perera, Travis Rogers, Ela Patel, Marco Sandri, Derya Tilki, Vipul Patel
Background and objective Robot-assisted radical prostatectomy (RARP) is the main surgical approach for treatment of prostate cancer in the USA. Prostate size is always depicted as a factor affecting the outcomes of RARP as shown by many studies, but these studies are limited to a small number of patients. Our aim was to evaluate functional and oncologic outcomes of RARP across varying prostate size
-
Validation of a Zero-shot Learning Natural Language Processing Tool to Facilitate Data Abstraction for Urologic Research Eur. Urol. Focus (IF 5.4) Pub Date : 2024-01-25 Basil Kaufmann, Dallin Busby, Chandan Krushna Das, Neeraja Tillu, Mani Menon, Ashutosh K. Tewari, Michael A. Gorin
Background Urologic research often requires data abstraction from unstructured text contained within the electronic health record. A number of natural language processing (NLP) tools have been developed to aid with this time-consuming task; however, the generalizability of these tools is typically limited by the need for task-specific training. Objective To describe the development and validation of
-
Reply to Marco Moschini, Francesco Montorsi, Andrea Salonia, Giorgio Gandaglia and Alberto Briganti’s Letter to the Editor Re: Francesco Soria, Matteo Rosazza, Simone Livoti, et al. Repeat Transurethral Resection (TUR) + Bacillus Calmette-Guérin (BCG) Versus Upfront Induction BCG After TUR in High-risk Non–muscle-invasive Bladder Cancer: Feasibility Phase of a Randomized Controlled Study. Eur Urol Eur. Urol. Focus (IF 5.4) Pub Date : 2024-01-25 Francesco Soria, Paolo Gontero
Abstract not available
-
Re: Christopher D. Gaffney, Andrew Katims, Neeta D’Souza, Marc A. Bjurlin, Richard S. Matulewicz. Bladder Cancer Carcinogens: Opportunities for Risk Reduction. Eur Urol Focus 2023;9:575–8 Eur. Urol. Focus (IF 5.4) Pub Date : 2024-01-25 Yu-Hsiang Lin, Han-Yu Tsai, Horng-Heng Juang
Abstract not available
-
Biophotonics—Intraoperative Guidance During Partial Nephrectomy: A Systematic Review and Meta-analysis Eur. Urol. Focus (IF 5.4) Pub Date : 2024-01-25 Luisa Egen, Greta S. Demmel, Maurizio Grilli, Alexander Studier-Fischer, Felix Nickel, Caelan M. Haney, Julia Mühlbauer, Friedrich O. Hartung, Hanna S. Menold, Pietro Piazza, Juan Gomez Rivas, Enrico Checcucci, Stefano Puliatti, Ines Rivero Belenchon, Mark Taratkin, Severin Rodler, Giovanni Cacciamani, Maurice S. Michel, Karl-Friedrich Kowalewski
Context Partial nephrectomy (PN) with intraoperative guidance by biophotonics has the potential to improve surgical outcomes due to higher precision. However, its value remains unclear since high-level evidence is lacking. Objective To provide a comprehensive analysis of biophotonic techniques used for intraoperative real-time assistance during PN. Evidence acquisition We performed a comprehensive
-
Re: Francesco Soria, Matteo Rosazza, Simone Livoti, et al. Repeat Transurethral Resection (TUR) + Bacillus Calmette-Guérin (BCG) Versus Upfront Induction BCG After TUR in High-risk Non–muscle-invasive Bladder Cancer: Feasibility Phase of a Randomized Controlled Study. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.10.019 Eur. Urol. Focus (IF 5.4) Pub Date : 2024-01-24 Francesco Montorsi, Marco Moschini, Andrea Salonia, Giorgio Gandaglia, Alberto Briganti
Abstract not available
-
Re: Antonio Andrea Grosso, Agostino Tuccio, Matteo Salvi, Daniele Paganelli, Andrea Minervini, and Fabrizio Di Maida’s Letter to the Editor re: Paolo Capogrosso, Eugenio Ventimiglia, Giuseppe Fallara, et al. Holmium Laser Enucleation of the Prostate Is Associated with Complications and Sequelae Even in the Hands of an Experienced Surgeon Following Completion of the Learning Curve. Eur Urol Focus 2023;9:813–21 Eur. Urol. Focus (IF 5.4) Pub Date : 2024-01-24 Yu-Hsiang Lin, Syue-Ting Chen, Horng-Heng Juang
Abstract not available
-
Oncologic Outcome of the Extent of Pelvic Lymph Node Dissection During Radical Prostatectomy: A Systematic Review, Meta-analysis, and Network Analysis Eur. Urol. Focus (IF 5.4) Pub Date : 2024-01-18 David E. Hinojosa-Gonzalez, Jose I. Nolazco, Gal Saffati, Shane Kronstedt, Jeffrey A. Jones, Dov Kadmon, Justin Badal, Jeremy R. Slawin
Context Some authors propose extended pelvic lymph node dissection (ePLND) to enhance diagnostic and therapeutic outcomes in patients with localized prostate cancer. However, recent evidence found no difference in biochemical recurrence (BCR). Objective To stratify and analyze available evidence on ePLND and its impact on BCR in patients with localized prostate cancer. Evidence acquisition We systematically
-
The Financial Burden of Guideline-recommended Cancer Medications for Metastatic Urothelial Carcinoma Eur. Urol. Focus (IF 5.4) Pub Date : 2024-01-09 Roberto Contieri, Alberto Martini, Laura S. Mertens, Patrizia Giannatempo, Rodolfo Hurle, J. Alfred Witjes, Maria J. Ribal, Bas W.G. van Rhijn, Bernard Malavaud
Bladder cancer is a significant global health concern owing to its prevalence, negative impact on quality of life, and high treatment costs. Treatment for metastatic urothelial carcinoma (mUC) traditionally relies on platinum-based chemotherapy regimens. However, clinical trial results have led to the approval of immune checkpoint inhibitors (ICIs) as viable treatment options. We assessed the escalating
-
The Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Primary Staging of Selected Renal Tumours: Initial Experience in a Multicentre Cohort Eur. Urol. Focus (IF 5.4) Pub Date : 2024-01-08 Arsalan Tariq, Adam Pearce, Handoo Rhee, Samuel Kyle, Sheliyan Raveenthiran, Anita Pelecanos, Chun Loo Gan, Jeffrey C. Goh, David Wong, Rhiannon McBean, Phillip Marsh, Steven Goodman, Nigel Dunglison, Rachel Esler, Anojan Navaratnam, John W. Yaxley, Paul Thomas, David A. Pattison, Matthew J. Roberts
Background Accurate primary staging of renal cancer with conventional imaging is challenging. Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) may serve to improve the accuracy of renal cancer staging. Objective To determine clinicopathological and management differences for primary renal cancer staged with PSMA PET/CT in comparison to conventional
-
Corrigendum to “A systematic review and meta-analysis on the impact of infertility on men’s general health” [Eur. Urol. Focus (2023) in press] Eur. Urol. Focus (IF 5.4) Pub Date : 2024-01-05 Giuseppe Fallara, Edoardo Pozzi, Federico Belladelli, Luca Boeri, Paolo Capogrosso, Giovanni Corona, Alessia D'Arma, Massimo Alfano, Francesco Montorsi, Andrea Salonia
Abstract not available
-
Treatment Patterns and Real-World Outcomes for Locally Advanced or Metastatic Urothelial Cancer in the Era of Immunotherapy Eur. Urol. Focus (IF 5.4) Pub Date : 2023-12-30 Melanie R. Hassler, Verena Moedlagl, Hanna Hindinger, Johanna Krauter, Sonja Klager, Irene Resch, Nicolai Huebner, Ozan Yurdakul, Heidemarie Ofner, Stephan M. Korn, David D'Andrea, Kilian Gust, Shahrokh F. Shariat
Background and objective There are limited data on real-world outcomes for patients with advanced or metastatic urothelial cancer (mUC) since immune checkpoint inhibitors (ICIs) became available. Our objective was to analyze outcomes for patients with mUC since ICIs became available. Methods We performed a retrospective analysis of 131 patients with mUC attending the outpatient clinic of a single tertiary
-
Re: Francesco Pellegrino, Armando Stabile, Gabriele Sorce, et al. Added Value of Prostate-Specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.10.006 Eur. Urol. Focus (IF 5.4) Pub Date : 2023-12-30 Alessio Guidotti, Daniele Fiasconaro, Antonio Nacchia, Riccardo Lombardo, Giorgio Franco, Cosimo De Nunzio
Abstract not available
-
Will Aquablation Be the New Benchmark for Robotic Minimally Invasive Surgical Treatment for Benign Prostatic Hyperplasia? Eur. Urol. Focus (IF 5.4) Pub Date : 2023-12-29 Carlotta Nedbal, Daniele Castellani, Virgilio De Stefano, Carlo Giulioni, Rossella Nicoletti, Giacomo Pirola, Jeremy Yuen-Chun Teoh, Dean Elterman, Bhaskar Kumar Somani, Vineet Gauhar
Background and objective Aquablation is included in the European Association Urology guidelines as an alternative surgical technique for prostate resection. The evidence summary states that it is subjectively and objectively as effective as transurethral resection of the prostate (TURP) and enucleation, but concerns remain regarding postoperative bleeding. Our aim was to provide an evidence-based overview
-
Potential Applications of New Headsets for Virtual and Augmented Reality in Urology Eur. Urol. Focus (IF 5.4) Pub Date : 2023-12-29 Fabio Zattoni, Filippo Carletti, Gianmarco Randazzo, Arianna Tuminello, Giovanni Betto, Giacomo Novara, Fabrizio Dal Moro
Virtual and augmented reality (VR/AR) technologies hold great promise in various medical fields. The release of a new generation of headsets for medical enhanced VR/AR (MER) opens new possibilities for applications in medicine, particularly in urology, to improve accessibility to everyone. These innovative headsets offer deep immersion without requiring a controller, which represents a novel approach
-
-
-
Patient and Urologist Perspectives on the Importance of Outcomes After Treatment of Hydrocele: A Multinational Survey Eur. Urol. Focus (IF 5.4) Pub Date : 2023-12-09 Angie K. Puerto Nino, Gordon H. Guyatt, Mikko Forss, Tuomas Kilpeläinen, , Kari A.O. Tikkinen
Abstract not available
-
Systematic Review and Meta-analysis of Minimally Invasive Procedures for Surgical Inguinal Nodal Staging in Penile Carcinoma Eur. Urol. Focus (IF 5.4) Pub Date : 2023-12-09 Isabella Greco, Sergio Fernandez-Pello, Vasileios I. Sakalis, Lenka Barreto, Maarten Albersen, Benjamin Ayres, Tiago Antunes Lopes, Riccardo Campi, Juanita Crook, Herney A. García Perdomo, Peter A.S. Johnstone, Mithun Kailavasan, Kenneth Manzie, Jack David Marcus, Andrea Necchi, Pedro Oliveira, John Osborne, Lance C. Pagliaro, Arie S. Parnham, Curtis A. Pettaway, Oscar R. Brouwer
Context There are several procedures for surgical nodal staging in clinically node-negative (cN0) penile carcinoma. Objective To evaluate the diagnostic accuracy, perioperative outcomes, and complications of minimally invasive surgical procedures for nodal staging in penile carcinoma. Evidence acquisition A systematic review of the Medline, Embase, and Cochrane controlled trials databases and ClinicalTrials
-
-
-
Clinical Trials and Climate Change: Doing Our Part While Pursuing Progress Eur. Urol. Focus (IF 5.4) Pub Date : 2023-12-01 Syed Rahman, Stephen Ryan, Joseph Kim, Patrick Kenney, Fady Ghali
Abstract not available
-
Confronting the Climate Emergency in Urology Eur. Urol. Focus (IF 5.4) Pub Date : 2023-12-01 Michael S. Leapman
Abstract not available
-
Reuse and Reprocessing of Endoscopic Instruments: For Eur. Urol. Focus (IF 5.4) Pub Date : 2023-11-30 Kevin Koo, Kevin M. Wymer, Aaron M. Potretzke
Abstract not available
-
The Impact of Telemedicine in Reducing the Carbon Footprint in Health Care: A Systematic Review and Cumulative Analysis of 68 Million Clinical Consultations Eur. Urol. Focus (IF 5.4) Pub Date : 2023-11-29 Severin Rodler, Lorenzo Storino Ramacciotti, Marissa Maas, Daniel Mokhtar, Jacob Hershenhouse, Andre Luis De Castro Abreu, Gerhard Fuchs, Christian G. Stief, Inderbir S. Gill, Giovanni E. Cacciamani
Context Carbon footprint (CF) has emerged as an important factor when assessing health care interventions. Objective To investigate the reduction in CF for patients utilizing telemedicine. Evidence acquisition The PubMed, Scopus, and Web of Science databases were queried for studies describing telemedicine consultation and reporting on carbon emissions saved and the carbon emissions of telemedicine
-
A Green Prescription: Integrating Environmental Sustainability in Urology Guidelines Eur. Urol. Focus (IF 5.4) Pub Date : 2023-11-29 Alina Herrmann, Felice E.E. van Veen, Bertil F.M. Blok, Kara L. Watts
Against the background of the climate crisis, there is an urgent need to include environmental sustainability recommendations in clinical practice guidelines. We highlight five domains for which suitable recommendations could help in mitigating the environmental impact of urology practice. Patient summary Climate change is an urgent issue that requires global action. Guidelines published by urological
-
Cognitive Prehabilitation: How Can We Counter Neurocognitive Frailty? Eur. Urol. Focus (IF 5.4) Pub Date : 2023-11-27 Adam Fink, Michelle Humeidan, Itay Bentov
Cognitive prehabilitation is a safe and inexpensive adjunct to multimodal prehabilitation to reduce the incidence of postoperative neurocognitive disorders, with the hypothesis that the brain can be prepared for the stress of surgery as for any other organ system. Recent trials have mostly focused on computerized, tablet-based interventions. More research is needed to define the utility and efficacy
-
Re: Guohua Zeng, Wen Zhong, Christian G. Chaussy, et al. International Alliance of Urolithiasis Guideline on Shockwave Lithotripsy. Eur Urol Focus 2023;9:513–23 Eur. Urol. Focus (IF 5.4) Pub Date : 2023-11-25 Ben H. Chew
Abstract not available
-
Effect of Recipient Body Mass Index on Kidney Transplantation Outcomes: A Systematic Review and Meta-analysis by the Transplant Committee from the French Association of Urology Eur. Urol. Focus (IF 5.4) Pub Date : 2023-11-22 Thomas Prudhomme, Lucas Bento, Alexandre Frontczak, Marc-Olivier Timsit, Romain Boissier
Context The impact of recipient obesity on kidney transplantation (KT) outcomes remains unclear. Objective The aim of this study was to perform a systematic review and meta-analysis to appraise all available evidence on the outcomes of KT in obese patients (body mass index [BMI] ≥30 kg/m2) versus nonobese patients (BMI <30 kg/m2). Evidence acquisition A systematic review and meta-analysis was performed
-
Quinolone Prophylaxis in Conjunction with Bacillus Calmette-Guérin Instillations for Bladder Cancer: Time To Reconsider the Evidence and Open the Quinolone Box? Eur. Urol. Focus (IF 5.4) Pub Date : 2023-11-22 Fredrik Liedberg, Evanguelos Xylinas, Paolo Gontero
Adjuvant bacillus Calmette-Guérin (BCG) instillations represent a cornerstone in the treatment of non–muscle-invasive bladder cancer. Instillation schedule and dose modifications have been evaluated in efforts to reduce the incidence of adverse events (AEs), but none so far has the same treatment efficacy as the full-dose recommended schedule. It has been shown that prophylactic quinolone use in conjunction
-
Integrating Prehabilitation into the Cancer Survivorship Framework Eur. Urol. Focus (IF 5.4) Pub Date : 2023-11-22 Julie K. Silver, Laura E. Flores
Prehabilitation is part of the oncology care continuum and may improve a patient’s physical and psychological health before surgery or starting a new cancer therapy.
-
Optimal Strategies for Managing Prostate-specific Antigen Recurrence After Primary Radiotherapy in Prostate Cancer: The Finnish Perspective Eur. Urol. Focus (IF 5.4) Pub Date : 2023-11-21 Heikki Seikkula, Lauri Mäkelä, Harri Visapää, Mikael Anttinen
Abstract not available
-
Safety and Efficacy of Vaginal Implants in Pelvic Organ Prolapse Surgery: A Meta-analysis of 161 536 Patients Eur. Urol. Focus (IF 5.4) Pub Date : 2023-11-14 Júlia Ács, Anett Szabó, Péter Fehérvári, Andrea Harnos, Benjamin Skribek, Martin Tenke, Tibor Szarvas, Péter Nyirády, Nándor Ács, Péter Hegyi, Attila Majoros
Context Among the many surgical treatments for pelvic organ prolapse (POP), better results can be achieved with the use of vaginal implants. However, owing to perceived complications, vaginal implant surgeries have been restricted or banned in many countries. Objective To assess the real value of vaginal implants in POP surgery and compare the safety and efficacy of operations with and without implants
-
Complications of Synthetic Midurethral Slings: Is There a Relevant Discrepancy Between Observational Data and Clinical Trials? Eur. Urol. Focus (IF 5.4) Pub Date : 2023-11-14 Fawzy Farag, N.I. Osman, K.H. Pang, D. Castro-Diaz, C.R. Chapple, F. Cruz, X. Gamé, H. Goldman, T. Greenwell, C. Hampel, L.M. Scailteux, J.P. Roovers, B. Welk, J. Heesakkers
Context The complications of synthetic midurethral slings (MUSs) in women with stress urinary incontinence (SUI) have become a globally debated issue. Objective To systematically review the short- and long-term complications of mesh slings reported in observational data compared with clinical trial data, to determine whether the complication rates from clinical trials reflects “real-world” observational
-
Evidence based Urology: The Gist Leading Us to the Evidence for Decisions Eur. Urol. Focus (IF 5.4) Pub Date : 2023-11-14 Imad Bentellis, Philippe D. Violette
Abstract not available
-
Summary Paper of the Updated 2023 European Association of Urology Guidelines on Urological Trauma Eur. Urol. Focus (IF 5.4) Pub Date : 2023-11-13 Efraim Serafetinidis, Felix Campos-Juanatey, Peter Hallscheidt, Husny Mahmud, Erik Mayer, Natasha Schouten, Davendra M. Sharma, Marjan Waterloos, Kristin Zimmermann, Noam D. Kitrey
Context The European Association of Urology (EAU) Guidelines Panel for Urological Trauma has produced guidelines in order to assist medical professionals in the management of urological trauma in adults for the past 20 yr. It must be emphasised that clinical guidelines present the best evidence available to the experts, but following guideline recommendations will not necessarily result in the best
-
Evidence-based Urology: Introduction to Our Second Series of Articles Eur. Urol. Focus (IF 5.4) Pub Date : 2023-11-08 Kari A.O. Tikkinen, Gordon H. Guyatt
Abstract not available
-
Laser Ablation Efficiency, Laser Ablation Speed, and Laser Energy Consumption During Lithotripsy: What Are They and How Are They Defined? A Systematic Review and Proposal for a Standardized Terminology Eur. Urol. Focus (IF 5.4) Pub Date : 2023-11-07 Jia-Lun Kwok, Vincent De Coninck, Eugenio Ventimiglia, Frédéric Panthier, Mariela Corrales, Alba Sierra, Esteban Emiliani, Michele Talso, Arkadiusz Miernik, Peter Kronenberg, Dmitry Enikeev, Bhaskar Somani, Khurshid R. Ghani, Olivier Traxer, Etienne Xavier Keller
Context Laser performance for lithotripsy is currently reported using units of measurement such as J/mm3, mm3/J, mm3/s, s/mm3, and mm3/min. However, there are no current standardized definitions or terminology for these metrics. This may lead to confusion when assessing and comparing different laser systems. Objective The primary objective was to summarize outcome values and corresponding terminology
-
How Best to Implement Climate-smart Actions in Clinical Urologic Care Eur. Urol. Focus (IF 5.4) Pub Date : 2023-11-07 Benjamin Pradere, Vincent Misraï, Michael Baboudjian
Abstract not available
-
Is It Worth the Sweat? Prehabilitation in Uro-oncology: A Mini Review Eur. Urol. Focus (IF 5.4) Pub Date : 2023-11-07 Silvan Sigg, Kristin Zeidler, Christian Daniel Fankhauser
Preoperative exercise initiatives might improve short-term functional results and reduce hospital length of stay and the incidence of postoperative complications after uro-oncological surgeries. However, further investigations are warranted.
-
Fixed-effect Versus Random-effects Models for Meta-analyses: Random-effects Models Eur. Urol. Focus (IF 5.4) Pub Date : 2023-11-07 Alex L.E. Halme, Kristen McAlpine, Alberto Martini
Abstract not available
-
Repeat Transurethral Resection (TUR) + Bacillus Calmette-Guérin (BCG) Versus Upfront Induction BCG After TUR in High-risk Non–muscle-invasive Bladder Cancer: Feasibility Phase of a Randomized Controlled Study Eur. Urol. Focus (IF 5.4) Pub Date : 2023-11-03 Francesco Soria, Matteo Rosazza, Simone Livoti, Daniele Dutto, Fulvia Colucci, Richard J. Sylvester, Shahrokh F. Shariat, Marek Babjuk, Joan Palou, Paolo Gontero
Background High-level evidence supporting the role of repeat transurethral resection (reTUR) in non–muscle-invasive bladder cancer (NMIBC) is lacking. A randomized controlled trial (RCT) assessing whether immediate reTUR has an impact on patient prognosis is essential. However, since such a RCT will require enrollment of a high number of patients, a preliminary feasibility study is appropriate. Objective
-
How To Read a Network Meta-analysis Eur. Urol. Focus (IF 5.4) Pub Date : 2023-11-03 Angie K. Puerto Nino, Romina Brignardello-Petersen
Network meta-analysis (NMA) expands upon traditional meta-analysis by integrating three or more interventions. This allows comparing interventions using evidence from trials that have compared pairs of interventions directly, and indirect evidence through common comparators. We provide an overview of NMA concepts and considerations when interpreting results from a systematic review with a NMA and applying
-
How to Compose Platform Trials Eur. Urol. Focus (IF 5.4) Pub Date : 2023-11-03 Noel W. Clarke, Nicholas D. James
Platform trials are adaptive randomised controlled trials that address multiple questions using a single protocol, which reduces the time taken to reach a meaningful trial endpoint. This mini review provides a description of how to conceive, design, and carry out a platform trial in urology, using experience gained in the STAMPEDE trial. Patient summary Clinical trials to test how well a new drug or
-
Patients’ Trust in Artificial Intelligence–based Decision-making for Localized Prostate Cancer: Results from a Prospective Trial Eur. Urol. Focus (IF 5.4) Pub Date : 2023-11-01 Severin Rodler, Rega Kopliku, Daniel Ulrich, Annika Kaltenhauser, Jozefina Casuscelli, Lennert Eismann, Raphaela Waidelich, Alexander Buchner, Andreas Butz, Giovanni E. Cacciamani, Christian G Stief, Thilo Westhofen
Background Artificial intelligence (AI) has the potential to enhance diagnostic accuracy and improve treatment outcomes. However, AI integration into clinical workflows and patient perspectives remain unclear. Objective To determine patients’ trust in AI and their perception of urologists relying on AI, and future diagnostic and therapeutic AI applications for patients. Design, setting, and participants
-
Emerging Role of Mobile Applications and Wearable Devices for Prehabilitation in Urologic Oncology Eur. Urol. Focus (IF 5.4) Pub Date : 2023-11-01 Hanna Hunter, Nicole Bennington-McKay, Jessica Sher, Sarah P. Psutka, Cindy Lin
This mini-review discusses how mHealth and wearable devices have been integrated into prehabilitation programs for patients with urologic cancers. There is a growing body of research on the benefits of mHealth in prescribing exercise programs, monitoring physical activity, and providing patient education.